Get in Touch

Cutting Edge Immunotherapy for Peanut Allergy Presented at Biotech Showcase™ 2020

San Francisco, (January 13, 2020) – Intrommune Therapeutics presented an update today on their oral mucosal immunotherapy (OMIT) technology at the Biotech Showcase™, which occurs during the annual J.P. Morgan Healthcare Conference.

“We are very excited to provide investors an overview of our OMIT technology,” said Michael Nelson, CEO, Intrommune Therapeutics. “There is no FDA approved treatment currently available for peanut allergy, representing an enormous opportunity to fill this significant unmet need.”

Intrommune’s lead product, INT301, is being developed for the treatment of peanut allergies. INT301’s unique formulation is designed to desensitize an individual with peanut allergy using a toothpaste delivery system, protecting them in the event of accidental peanut exposure. More than 3 million people, including an estimated 1.6 million children, have peanut allergy in the U.S. If approved, INT301 has the potential to be the first allergy immunotherapy treatment that easily integrates into a person’s daily routine as both first-line and long-term maintenance therapy for peanut allergy.

OMIT enables consistent delivery of allergy immunotherapy while a user brushes their teeth. Intrommune Therapeutics obtained world-wide rights from Allovate Therapeutics to develop the OMIT platform for the treatment of food allergies (including peanut allergy). Over 15 million people in the U.S. and 17 million in Europe suffer from food allergies.

“The use of a patented toothpaste delivery platform is expected to improve allergy immunotherapy by increasing the precision of treatment delivery and promoting treatment adherence,” said Erick Berglund, PhD, Chief Scientific Officer. “OMIT delivers immunotherapy to the oral mucosa, which has the highest likelihood of initiating allergy desensitization. Targeted delivery of medication is expected to decrease the rate of side effects linked to swallowing food allergy proteins, including eosinophilic esophagitis, gastrointestinal discomfort and potentially life-threatening anaphylaxis that requires the use of emergency epinephrine.”

About Oral Mucosal Immunotherapy

Oral mucosal immunotherapy (OMIT) uses a specially formulated toothpaste to stabilize and deliver allergenic proteins to immunologically active areas of the oral cavity with the greatest potential for allergy desensitization. Success with allergy immunotherapy hinges on consistent exposure of a patient’s immune system to gradually “desensitize” the patient to the specific allergy trigger over time. OMIT promises advantages over other approaches to allergy immunotherapy due to its targeted delivery, simplified administration, and support of reliable, long-term adherence.

About Intrommune Therapeutics

Intrommune, dedicated to improving and protecting the lives of people with food allergy, is developing the revolutionary oral mucosal immunotherapy (OMIT) treatment platform for food allergies. OMIT is a long-term, patient-friendly immunotherapy for the 220 million people, including more than 9 million adults and 6 million children in the U.S., who suffer from life-altering food allergies. Intrommune’s lead product, INT301, is expected to be a safe, effective and convenient therapy for patients who suffer from peanut allergy. For more information on Intrommune Therapeutics, please follow the link to http://www.intrommune.com/investors/

Cautionary Statement Regarding Forward Looking Statements

This release may contain "forward-looking statements." Forward-looking statements are identified by certain words or phrases such as "may," "will," "aim," "will likely result," "believe," "expect," "will continue," "anticipate," "estimate," "intend," "plan," "contemplate," "seek to," "future," "objective," "goal," "project," "should," "will pursue" and similar expressions or variations of such expressions. These forward-looking statements reflect the company's current expectations about its future plans and performance. These forward-looking statements rely on a number of assumptions and estimates which could be inaccurate and which are subject to risks and uncertainties. Actual results could vary materially from those anticipated or expressed in any forward-looking statement made by the company. The company disclaims any obligation or intent to update the forward-looking statements in order to reflect events or circumstances after the date of this release.

This release does not contain or constitute an offer to sell or a solicitation of any offer to buy securities in the United States or in any other jurisdiction.

Key Takeaways
  • Intrommune presents update on oral mucosal immunotherapy for peanut allergy
  • There is no FDA approved treatment currently available for peanut allergy, representing an enormous opportunity to fill this significant unmet need.
  • INT301’s unique formulation is designed to desensitize an individual with peanut allergy using a toothpaste delivery system, protecting them in the event of accidental peanut exposure.
Video Gallery
Intrommune Therapeutics
View on Youtube
Intrommune Therapeutics moving its peanut allergy treatment through the FDA approval process
View on Youtube
Media Gallery
Quotes
There is no FDA approved treatment currently available for peanut allergy, representing an enormous opportunity to fill this significant unmet need.
Michael Nelson, JDCEO
The use of a patented toothpaste delivery platform is expected to improve allergy immunotherapy by increasing the precision of treatment delivery a...
Erick Berglund, PhDChief Scientific Officer
Related Bios
Michael Nelson, JD
Chief Executive Officer
View Full Bio>>
Erick Berglund, PhD
Chief Scientific Officer
View Full Bio>>
Contacts
John F. Kouten
jfkouten@jfkhealth.com
609-241-7352
JFK Communications, Inc.
Michelle Mantia
mmantia@intrommune.com
Outreach Manager Intrommune Therapeutics